Clinical and histological features of delta infection in chronic hepatitis B virus carriers

ASF LOK, I LINDSAY, PJ SCHEUER, HC THOMAS

From the Departments of Medicine and Histopathology, Royal Free Hospital and School of Medicine, London NW3

SUMMARY One hundred and six consecutive chronic hepatitis B virus (HBV) carriers were studied for the prevalence of delta markers in serum and tissue, and the clinical and histological features of those with and without delta infection were compared. Twenty (18.9%) patients were positive for anti-delta in serum or delta antigen in the liver or both. They presented at a younger age (30.3 ± 38 years). All of them were symptomatic at the time of biopsy, in contrast to 35% of patients without delta infection who were not symptomatic. Those with delta infection had higher serum transaminase values and showed more severe liver damage on biopsy: chronic active hepatitis in 45% and cirrhosis in 55%. There was more pronounced disease activity both within the parenchyma and in the portal and periportal zones. The histological diagnosis of the 86 patients without delta infection included minimal disease (10%), chronic persistent hepatitis (9%), chronic active hepatitis (62%), and cirrhosis (19%). Delta infection in chronic HBV carriers is associated with a more active and progressive liver disease.

The delta agent is a defective hepatitis virus with a putative ribonucleic acid genome. It requires the presence of hepatitis B virus (HBV) for its replication. It was first described in 1977 in an Italian chronic HBV carrier. Since then, epidemiological studies have shown that it occurs worldwide, but it is most common in Mediterranean countries. In northern Europe and America the prevalence of delta antibody in the serum or of delta antigen in mainly to drug addicts and multiply transfused subjects.

The diagnosis of coexistent delta infection in chronic HBV carriers depends on the detection of delta antibody in the serum or of delta antigen in the liver. Delta antigen in serum is detectable in only a minority of patients during the early stages of infection. The presence of delta infection in a chronic HBV carrier usually results in a more severe and rapidly progressive type of liver disease. Certain histological features have been reported to be associated with delta infection, but these are too non-specific to be of any great diagnostic use.

To determine the effect of delta infection on the course and severity of the liver disease in chronic HBV carriers we conducted a retrospective study to analyse the prevalence of delta markers and to compare the clinical and histological features of those with and without delta infection.

Material and methods

PATIENTS One hundred and six consecutive chronic HBV carriers referred to the Department of Medicine at the Royal Free Hospital were studied. All of them had had liver biopsies performed between January 1980 and June 1982. The patients had been hepatitis B surface antigen (HBsAg) positive for at least six months. Patients who had received antiviral or immunosuppressive treatment during the three months before biopsy and those in whom an alternative cause for the liver disease was suspected were excluded.

SEROLOGY HBsAg, hepatitis Be antigen (HBeAg), and anti-HBe were tested by radioimmunoassay (Abbott Laboratories). Serum samples taken at the time of liver biopsy were stored at −20°C, coded, and sent for blind analysis of antidelta by a solid phase blocking radioimmunoassay (kindly performed by Dr M Rizzetto, Department of Medicine, Turin). HBV-DNA was measured by dot/blot hybridisation.
Clinical and histological features of delta infection in chronic hepatitis B virus carriers

INTRAHEPATIC DELTA ANTIGEN

This was detected by immunoperoxidase staining. Routine 4 μm sections were dewaxed, taken to alcohol, and treated for 30 min with 1% hydrogen peroxide solution in methanol to block endogenous peroxidase activity. Slides were trypsinised for 8 min at 37°C using a 0-1% trypsin (Sigma Type 11) in 0-1% calcium chloride solution at pH 7-4. After washing, they were incubated with a peroxidase conjugated human antidelta IgG (kindly provided by Dr M Rizzetto), diluted to 1/70 in phosphate buffered saline (PBS). After washing in PBS the peroxidase reaction product was demonstrated using 3'3' diaminobenzidine (BHD) after the method of Graham and Karnovsky.11 Slides were washed, counterstained with Carrazzi’s haematoxylin, dehydrated, and mounted.

HISTOLOGICAL DIAGNOSIS

Diagnoses were made according to generally accepted criteria,12 and patients were classified as having minimal disease, chronic persistent hepatitis, chronic active hepatitis with or without cirrhosis, or inactive cirrhosis. The activity of the liver disease was assessed by a pathologist (IL), who was unaware of the serological status, and an activity index (0-4) was recorded for both the portal zones and the parenchyma. In portal zones a score of 1 denoted inflammatory infiltration without piecemeal necrosis (chronic persistent hepatitis), while scores of 2, 3, and 4 denoted mild, moderate, and severe piecemeal necrosis (chronic active hepatitis) respectively; parenchymal score 1 denoted inflammation without necrosis. Scores 2, 3, and 4 were used for varying degrees of hepatocellular necrosis and inflammation. Scores of 0 were allotted when inflammation and necrosis were absent.

STATISTICAL ANALYSIS

Student’s t test was used to compare the mean ages, serum transaminase values, and activity indices of the patients with and without delta infection.

Table 1  Characteristics of chronic hepatitis B virus carriers with and without delta infection

<table>
<thead>
<tr>
<th></th>
<th>Delta positive</th>
<th>Delta negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>20</td>
<td>86</td>
</tr>
<tr>
<td>HBeAg positive</td>
<td>5</td>
<td>50</td>
</tr>
<tr>
<td>Anti-HBe positive</td>
<td>15</td>
<td>36</td>
</tr>
<tr>
<td>Sex ratio (M:F)</td>
<td>18:2</td>
<td>81:5</td>
</tr>
<tr>
<td>Age (yr) (range)</td>
<td>30-3 (18-51)</td>
<td>38 (14-62)</td>
</tr>
</tbody>
</table>

HBeAg = hepatitis B e antigen.

Results

Twenty of the 106 patients with HBV induced chronic liver disease (18-9%) had evidence of delta infection as shown by high titre antidelta in the serum or delta antigen in the hepatocyte nuclei or both. Five of these patients were HBeAg positive and 15 were anti-HBe positive. Fifty of the 86 patients without delta infection were HBeAg positive and the remaining 36 were anti-HBe positive. There was a preponderance of men in the patients with delta infection and in those without (male:female 18:2 and 81:5, respectively) (Table 1). The patients with delta infection presented at a younger age. Their mean age at the time of biopsy was 30-3 years (18-57), while the mean age of those without delta infection was 38 years (14-62) (p < 0-05). Nine of 15 delta positive, anti-HBe positive carriers were tested for HBV-DNA and all were negative.

ETHNIC ORIGINS AND POSSIBLE MODES OF TRANSMISSION

Table 2 shows the prevalence of delta infection in the various clinical groups. All seven British patients were either parenteral drug abusers or haemophiliacs; four of the remaining 13 were drug addicts but none was haemophiliac. By comparison, there were six addicts and one haemophiliac among the 86 patients without delta infection. Delta markers were

Table 2  Prelavence of delta infection among the different ethnic groups and the possible modes of transmission of delta agent

<table>
<thead>
<tr>
<th>Ethnic origin</th>
<th>No studied</th>
<th>No positive for delta infection (%)</th>
<th>Addicts</th>
<th>Haemophiliacs</th>
</tr>
</thead>
<tbody>
<tr>
<td>British</td>
<td>49</td>
<td>7 (14-3)</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Mediterranean</td>
<td>29</td>
<td>6 (20-1)</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Middle Eastern</td>
<td>13</td>
<td>5 (38-5)</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Oriental</td>
<td>9</td>
<td>0 (0)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>African</td>
<td>4</td>
<td>1 (25)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Central American</td>
<td>2</td>
<td>1 (50)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>106</td>
<td>20 of 106 (18-9%)</td>
<td>10</td>
<td>1</td>
</tr>
</tbody>
</table>

Downloaded from http://jcp.bmj.com/ on May 2, 2017 - Published by group.bmj.com
not detected in any of the 26 homosexuals studied, 23 of whom were British.

**CLINICAL PRESENTATION** (Table 3)

A history of acute hepatitis was elicited in 14 (70%) of 20 patients with delta infection but in only 26 (30%) of 86 patients without coexistent delta infection. All the patients with delta infection were asymptomatic at the time of biopsy. Five of them presented with late complications of chronic liver disease: portal hypertension in two and hepatic failure in three. In contrast, 65% (56/86) of patients without delta infection were asymptomatic. The remaining patients had mild symptoms. Only five presented with portal hypertension, and none was in hepatic failure at the time of biopsy.

**SERUM TRANSAMINASE VALUES**

The mean serum transaminase (AST) values at the time of biopsy were significantly higher (p < 0.01) in those with delta infection (average 121 IU/l, range 56–280) than in those without (average 60, range 20–210).

**HISTOLOGICAL CHANGES** (Table 4)

Those with delta infection had more severe liver disease on biopsy. Nine (45%) had chronic active hepatitis, mainly moderate or severe in activity, and the remaining 11 (55%) had active cirrhosis. The histological diagnoses of the remaining 86 patients were more varied: 17 (19%) had mild liver disease and only 16 (19%) had cirrhosis, mostly inactive. The mean activity indices in the patients with delta infection were significantly higher (p < 0.01): the difference in the parenchymal activity (2.6 v 1.14) was more striking than the difference in portal and periportal inflammation and necrosis (2.65 v 1.48).

**Discussion**

Coexistent delta infection was present in 18.9% of 106 patients with HBV induced chronic liver disease. In British patients the prevalence was 14.3%, which accords with the rates that have previously been reported, and was confined to the addicts and haemophiliacs. We did not find any delta markers in 26 homosexual carriers, 23 of whom were British. It has been suggested that there is little overlap between the addict and homosexual populations, based on differences in the HBsAg subtypes. An alternative explanation is that the inoculum transmitted sexually may be smaller than that transferred by the parenteral route, and perhaps insufficient to cause delta infection. In the chimpanzee, a 10^-8 dilution of serum containing HBV and delta agent results in loss of delta but not HBV infectivity.

Delta infection was found in 20–50% of patients from other parts of the world. In most of these the mode of transmission was not apparent. Studies in Italy have shown familial clustering of delta infection and it is possible that the delta agent may spread through other routes via close contacts in endemic areas.

The patients with delta infection presented at a significantly younger age. It is possible that our patients acquired HBV infection at comparable ages, but that coexistent delta infection produced a more severe disease and therefore earlier presentation. HBV infection may cause either a clinically obvious or a subclinical hepatitis, and our patients without delta infection may have remained undetected for many years. Indeed, at the time of biopsy, all our patients with delta infection were symptomatic, whereas most of those without delta infection were symptom free. A higher proportion of our patients with delta infection had histories of acute hepatitis, some having had more than one episode. This could represent an acute hepatitis B infection or acute hepatitis due to superinfection with delta agent in a chronic HBV carrier.

The patients with delta infection also had higher serum transaminase values and more severe liver disease on biopsy, with more striking activity in the parenchyma and to a lesser extent in the portal zones. The continuing parenchymal activity was surprising as the majority, 15, of our patients with delta
Clinical and histological features of delta infection in chronic hepatitis B virus carriers

infection were anti-HBe positive and therefore had low or undetectable rates of HBV replication. In certain geographical regions, such as the Mediterranean countries, despite a high spontaneous seroconversion rate from HBeAg to anti-HBe, up to 40% of patients who are anti-HBe positive may still have active viral replication with HBV-DNA in serum or hepatitis B core antigen in the liver. This may account for the persistently active liver disease in such patients. In our 15 patients with delta infection who were anti-HBe positive, however, all nine tested for serum HBV-DNA were negative, and only one of the six tested for hepatitis B core antigen in the liver was positive. Thus the increased activity of the liver disease in these patients could not be due to persistent HBV replication producing a continuous, immune mediated lysis of infected hepatocytes. Half of our patients with delta infection were drug addicts, and it is possible that some of them may also have had non-A, non-B hepatitis contributing to a more severe liver disease. In Italy, however, delta infection is endemic among HBV carriers and is not confined to addicts and haemophiliacs, but a more severe liver disease is still found.

Liver disease in HBV infection is believed to be the result of immunological attack on hepatocytes displaying viral antigens. It has been suggested that delta is a cytopathic agent, and that there may be synergistic liver damage in chronic HBV carriers with coexistent delta infection. This may not only potentiate existing liver damage but may also hasten the rate of progression. In our study five of the 20 patients with delta infection presented with late complications of chronic liver disease—namely, portal hypertension and hepatic failure. Over half, 55%, already had established cirrhosis on biopsy.

The discovery of the delta agent helps to explain why in certain chronic HBV carriers the liver disease may remain active and progressive despite low levels of HBV replication; delta markers in chronic HBV carriers indicate a more ominous prognosis. Clinical studies have shown that this severe and progressive liver disease is unresponsive to immunosuppressive therapy. The role of antiviral treatment has yet to be evaluated.

ASFL is supported by the University of Hong Kong. IL is a Wellcome Research Fellow.

References


Requests for reprints to: Dr HC Thomas, Academic Department of Medicine, Royal Free Hospital, Pond Street, London NW3 2QG, England.
Clinical and histological features of delta infection in chronic hepatitis B virus carriers.
A S Lok, I Lindsay, P J Scheuer and H C Thomas

J Clin Pathol 1985 38: 530-533
doi: 10.1136/jcp.38.5.530

Updated information and services can be found at:
http://jcp.bmj.com/content/38/5/530

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/